Research, development, consulting, and testing / assay services

BIOQUAL, Inc. specializes in preclinical testing and research services, focusing on infectious diseases, cancer research, and vaccine development. The company employs advanced methodologies to evaluate vaccines, therapeutics, and drug therapies, utilizing both in vivo and in vitro studies. Their research includes the use of non-human primate models, such as rhesus macaques and cynomolgus macaques, to investigate various viral infections, including HIV, Zika, and SARS-CoV-2. BIOQUAL's capabilities extend to immunogenicity studies, vaccine efficacy testing, and the assessment of immune responses to different vaccine platforms, including mRNA and adenovirus-based vectors.

In addition to their extensive animal model research, BIOQUAL offers a range of in vitro services, including virus quantitation, neutralization assays, and flow cytometry. Their commitment to high standards is reflected in their accreditation by the Association for the Assessment and Accreditation of Laboratory Animal Care International (AAALAC). The company collaborates with academic and governmental organizations to enhance global health through innovative research, contributing to the understanding of immune responses and the development of effective vaccines and therapies against infectious diseases.

United States

BIOQUAL, Inc. is fully accredited by the Association for the Assessment and Accreditation of Laboratory Animal Care International (AAALAC) and has a long history of providing state-of-the-art facilities and trained, experienced research scientists, veterinarians and animal care personnel for clients involved in infectious disease investigations, cancer research, and a wide variety of other in vivo and in vitro studies.

BIOQUAL, Inc.

Company Details